fda declares semaglutide shortage resolved february 2025 Federal judge upholds FDA's removal of Ozempic, Wegovy from drug list GLP-1 Drugs: FDA Removes Semaglutide

These results suggest that GLP-1/exendin-4 might compensate for the alterations in AMPK, activity produced either by oscillations in glucose levels or by pathologies such as obesity or episodes of hyperinsulinemia (Figure 5, 6)

This is why semaglutide was originally developed for type 2 diabetes before its appetite suppression effects were recognized

Washington, and Towson

The gold standard topical anti-aging intervention, and highly complementary to oral collagen supplementation

J Neurosurg 143:10371047, 2025 This multicenter propensity-matched cohort study examines the association between glucagon-like peptide-1 receptor agonist (GLP-1-RA) therapy and clinical, neurosurgical, and mortality outcomes in adult patients with idiopathic intracranial hypertension (IIH) using the TriNetX electronic health record network

The FDA maintains a page on interstate compounding restrictions that is worth reviewing [3]